The Sweetener Question: What the Sucralose-DNA Story Actually Shows

Posted on 14 September, 2026 by Mehrdad Fathi

Few stories in nutrition science travel as fast as one connecting a common food additive to DNA damage. When a 2023 study reported that a chemical linked to sucralose — the sweetener in Splenda — broke DNA strands in human cells, it moved quickly through health media. Three years later, the full picture is considerably more complicated, and considerably more instructive about how laboratory findings translate, or fail to translate, into actual risk.

The Chemical at the Center

The 2023 study, led by Susan Schiffman at North Carolina State University, did not examine sucralose directly. Its focus was sucralose-6-acetate, a structurally related compound that can appear as a manufacturing impurity in commercial sucralose at concentrations up to 0.67% in the samples the team analyzed. The researchers exposed cultured human blood cells to this compound and reported results consistent with genotoxicity — specifically, patterns associated with strand breaks in DNA.

They also tested the intestinal barrier. Using a laboratory model of human gut epithelial tissue, both sucralose and sucralose-6-acetate disrupted tight junctions between cells — the molecular interfaces that regulate what crosses from the gut into the bloodstream. Gene expression analysis of exposed cells showed increased activity in pathways associated with oxidative stress, inflammation, and carcinogenicity.

On the basis of these findings, Schiffman recommended that people avoid sucralose-containing products entirely, citing an exposure concern: she estimated that trace amounts of sucralose-6-acetate in a single daily sweetened drink could exceed the European Food Safety Authority’s threshold of toxicological concern for genotoxic substances, set at 0.15 micrograms per person per day.

That is where many versions of the story stopped. The actual scientific record did not.

What Context Does to the Findings

Three distinctions matter for reading the 2023 data accurately.

First, in vitro genotoxicity is not equivalent to clinical harm. Exposing cultured cells directly to a chemical reveals a potential hazard — a necessary early signal — but it does not establish whether that chemical reaches human tissues in sufficient concentration through normal consumption to produce the same effect. The 2023 experiments were not designed to, and did not, answer that question.

Second, the threshold of toxicological concern that Schiffman cited is a conservativ normal consumption to produce the same effect. The 2023 experiments were not designed to, and did not, answer that question.

Second, the threshold of toxicological concern that Schiffman cited is a conservative regulator closer assessment. Exceeding it triggers further evaluation; it does not, by itself, indicate that a substance causes disease.

Third, the metabolic pathway the researchers proposed — that sucralose breaks down in the body to form sucralose-6-acetate — was subsequently challenged. In its 2026 comprehensive reassessment, the European Food Safety Authority reviewed the earlier animal data on which that claim rested and noted that the compounds detected in rat urine and feces could have been impurities already present in the sucralose administered, rather than metabolic products. The formation pathway, a central premise of the concern, remains unconfirmed in humans.

The 2026 Regulatory Reassessment

In February 2026, EFSA published a full re-evaluation of sucralose as a food additive. Its expert panel retained the acceptable daily intake of 15 milligrams per kilogram of body weight per day — an amount considered safe for daily lifetime consumption — after finding that dietary exposure across assessed population groups remained below that level.

The panel reviewed the 2023 genotoxicity data directly and judged the relevant screening evidence to have limited relevance for its overall assessment. After integrating laboratory, animal, and human data, the panel found that sucralose’s use as a food additive did not raise a genotoxicity concern at levels representative of actual consumption.

The U.S. Food and Drug Administration has not revised its approval of sucralose, which was based on a safety review encompassing more than 110 studies including human clinical research.

A separate industry-affiliated study published in Food and Chemical Toxicology in August 2026 tested commercial-grade sucralose across multiple genetic toxicity assays in cells and animals, reporting negative results for mutations and chromosome damage. One comet assay did detect DNA damage signals in several tissues, but the authors described interpretive complications and concluded the overall dataset did not support a genotoxicity finding. The industry connections of several authors are relevant context for weighting this work, and it tested commercial sucralose rather than isolated sucralose-6-acetate, so it does not directly rebut the 2023 experiments — it addresses an adjacent but distinct question.

Other Biological Questions, Distinct from Genotoxicity

The DNA story has run alongside a separate set of questions about how sucralose interacts with appetite regulation and metabolic function. These are worth tracking independently.

A randomized study published in Nature Metabolism in March 2025 found that sucralose, compared with sugar, increased self-reported hunger and hypothalamic blood flow in 75 young adults — the hypothalamus being a central region in appetite regulation. These were acute responses, not evidence of long-term weight effects, but they add to a growing body of work suggesting the sweetener is not metabolically inert.

A systematic review of 23 randomized trials, published in August 2026, examined sucralose and cardiometabolic outcomes in healthy adults. Results on blood sugar regulation were mixed across studies, with some reporting unfavorable signals and others finding no effect. The review authors flagged ongoing uncertainty about metabolic consequences — questions that are distinct from the original genotoxicity claim but increasingly relevant to how the compound is assessed overall.

EFSA also identified an unresolved concern around high-temperature cooking: under certain baking and frying conditions, chlorine from sucralose may become incorporated into other compounds whose health effects remain uncertain. This is why the panel declined to endorse a proposed expansion of sucralose use in fine bakery wares — not because it confirmed the 2023 findings, but because a different category of unknowns at elevated temperatures has not been resolved.

What the Evidence Actually Supports

The 2023 research reported real signals in controlled laboratory conditions. Those signals were worth publishingy validated — that ordinary sucralose consumption damages DNA in people.

The regulatory picture as of 2026: two major food safety authorities have reviewed the compound and maintained its approval under current use conditions. The metabolr food safety authorities have reviewed the compound and maintained its approval under current use conditions. The metabolic pathway assumed sucralose have been largely negative. Concerns about high-temperature degradation products and metabolic effects on appetite and glucose regulation remain open, but they are different questions from the one the 2023 study raised.

That is not exoneration, and it is not dismissal. It is the scientific process doing what it is supposed to do: generating a hypothesis, subjecting it to scrutiny, and returning a more qualified answer than the original alarm suggested. For a substance consumed daily by hundreds of millions of people, that distinction is worth understanding precisely.

Source: North Carolina State University. “Popular sweetener byproduct damages DNA in human cells.” ScienceDaily, September 13, 2026. www.sciencedaily.com/releases/2026/09/260912220107.htm

References:

1. Schiffman, S.S. et al. Toxicological and pharmacokinetic properties of sucralose-6-acetate and its parent sucralose: in vitro screening assays. Journal of Toxicology and Environmental Health, Part B 26(6):307 (2023). DOI: 10.1080/10937404.2023.2213903

2. Castle, L. et al. Re-evaluation of sucralose (E 955) as a food additive. EFSA Journal 24(2) (2026). DOI: 10.2903/j.efsa.2026.9854

3. Gujral, J. et al. Genotoxicity and mutagenicity of commercial-grade sucralose: No concerns in modern bioassays. Food and Chemical Toxicology 217:116342 (2026). DOI: 10.1016/j.fct.2026.116342

4. Chakravartti, S.P. et al. Non-caloric sweetener effects on brain appetite regulation in individuals across varying body weights. Nature Metabolism 7(3):574 (2025). DOI: 10.1038/s42255-025-01227-8

5. Pérez Sendino, M. et al. Sucralose Intake and Cardiometabolic Outcomes in Healthy Adults: A Systematic Review of Randomized Controlled Trials. Endocrines 7(3):49 (2026). DOI: 10.3390/endocrines7030049